Terazosin is a quinazoline-derivative alpha-1-selective adrenoceptor blocking agent primarily indicated for the treatment of hypertension and symptomatic benign prostatic hyperplasia. Because accurate… Read more





![Chemical structure of 1-[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-5-hydroxy-1-pentanone-d8](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2732980-69-5-1-4-4-Amino-67-dimethoxy-2-quinazolinyl-1-piperazinyl-5-hydroxy-1-pentanone-d8.png&w=3840&q=75)




![Chemical structure of [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl][(5S)-tetrahydro-5-methyl-2-furanyl]methanone-d8](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2714488-83-0-4-4-Amino-67-dimethoxy-2-quinazolinyl-1-piperazinyl5S-tetrahydro-5-methyl-2-furanylmethanone-d8.png&w=3840&q=75)




















Terazosin is a quinazoline-derivative alpha-1-selective adrenoceptor blocking agent primarily indicated for the treatment of hypertension and symptomatic benign prostatic hyperplasia. Because accurate identification and quantification of related substances are critical in pharmaceutical manufacturing, this category provides a comprehensive selection of reference standards, including pharmacopeial and non-pharmacopeial impurities, synthetic intermediates, degradation products, and stable isotope-labelled compounds. These high-quality materials are essential for pharmaceutical laboratories performing rigorous impurity profiling, method validation, and routine quality control. By utilizing these characterized standards, researchers can effectively monitor process-related impurities, potential nitrosamine contaminants, and degradation pathways to ensure ongoing regulatory compliance and product safety. Whether supporting stability testing or analytical method development, these compounds provide the reliable, structurally confirmed benchmarks necessary for maintaining the therapeutic efficacy of this therapeutic agent.